Continual-G Challenges Liposomal Glutathione Study's Bioavailability Claims
Event summary
- A study in 'Antioxidants' reported liposomal glutathione increased whole blood levels for up to 24 hours.
- Continual-G's team argues the study only proves glutathione reaches the bloodstream, not cells.
- Continual-G's proprietary Glyteine® has clinical evidence of cellular bioavailability.
- Continual-G was launched in 2019 by Inid Research Lab LLC.
The big picture
The debate over glutathione supplementation highlights the growing importance of bioavailability evidence in the nutraceuticals market. Continual-G's focus on cellular-level benefits positions it as a potential leader in a space where many competitors rely on less specific claims. The industry may see increased scrutiny of bioavailability mechanisms as clinical evidence becomes more central to product differentiation.
What we're watching
- Product Differentiation
- How Continual-G's emphasis on cellular bioavailability will position it against competitors promoting liposomal formulations.
- Regulatory Scrutiny
- Whether the lack of cellular bioavailability evidence for liposomal glutathione will attract regulatory attention.
- Market Education
- The pace at which consumers and healthcare professionals differentiate between plasma and cellular bioavailability claims.